Creative Biolabs provides oncolytic herpes simplex virus (oHSV) engineering services for researchers developing tumor-selective, payload-armed, retargeted, or safety-enhanced HSV candidates with practical support from design review to rescue, characterization, and validation planning.
Herpes simplex virus is one of the most established oncolytic virus platforms because its large double-stranded DNA genome supports multi-gene engineering, its biology is well characterized, and its lytic replication can be reshaped through attenuation, transcriptional control, entry retargeting, and payload insertion.
Creative Biolabs designs oHSV engineering projects around the specific development question: how to improve tumor-selective replication, reduce normal-tissue risk, encode a therapeutic or imaging payload, alter entry behavior, or generate a candidate that is ready for in vitro validation, combination testing, or in vivo study planning.
The service can be used before construction to finalize an oHSV architecture or after prototype generation to troubleshoot replication, payload expression, tropism, stability, and validation readiness.
Assess HSV-1 or HSV-derived backbone, genome map, insertion locus, deletion history, packaging limits, rescue system, and intended development use.
Backbone fit assessment and recommended engineering strategy.
Review ICP34.5-, ICP47-, UL39-, TK-, US11-, promoter-controlled, or miRNA-compatible designs to tune tumor selectivity and safety margin.
Attenuation plan with replication and safety readout recommendations.
Plan cytokine, chemokine, antibody, checkpoint, bispecific, enzyme, suicide gene, imaging, or reporter cassettes with expression timing and burden considered.
Payload-ready cassette architecture and construct map notes.
Evaluate gD, gB, gH/gL, ligand fusion, antibody-fragment, or receptor-restriction concepts for tumor entry and normal-cell detargeting.
Entry engineering plan with receptor and infectivity assay design.
Support recombinant oHSV rescue feasibility, plaque isolation strategy, amplification, infectious titer, genome identity, and initial stock characterization.
Prototype oHSV stock and quality characterization package.
Evaluate infection, replication kinetics, payload expression, tumor-cell killing, immune readouts, normal-cell comparator response, and selected stability indicators.
Decision-ready validation dataset and next-step recommendations.
Oncolytic HSV Construction Services
Antibody-expressing Oncolytic Virus Production
Cytokine/Chemokine-expressing OV Production
Oncolytic Virus In Vitro Validation
Creative Biolabs builds the technical package according to the oHSV architecture and development decision point, connecting molecular design with virology, tropism, payload expression, and safety-oriented validation.
Deletion/insertion locus review, promoter selection, polycistronic cassette planning, payload orientation, sequence verification, and rescue feasibility review.
BAC-based or homologous recombination-compatible planning, rescue monitoring, plaque purification strategy, amplification, and stock preparation.
Infectious titer, qPCR-based genome copy analysis, replication kinetics, plaque phenotype, sequencing or locus confirmation, and selected passage stability checks.
Receptor-positive and receptor-negative cell panels, competition or blocking assays, glycoprotein design comparison, and infectivity selectivity profiling.
Reporter readouts, RT-qPCR, ELISA, western blot, flow cytometry, immunofluorescence, secretion analysis, and time-course expression profiling.
2D tumor panels, spheroid-compatible assays, immune co-culture, cytokine release, checkpoint pathway readouts, and combination therapy matrix design.
Normal cell comparators, replication restriction readouts, payload-related risk flags, neurovirulence-related design review, and early safety boundary assessment.
Engineered oHSV candidates should not be advanced based on rescue success alone. Creative Biolabs organizes design and assay evidence into a framework that makes the tradeoffs clear.
Whether the selected deletion or replication-control strategy reduces normal-cell risk without removing the replication strength needed for tumor killing.
Impact of engineering changes on rescue, plaque phenotype, titer, genome identity, replication kinetics, and candidate stability.
Expression level, secretion or localization, timing relative to infection, functional activity, and burden on viral fitness.
Evidence that glycoprotein or receptor-targeting designs improve tumor entry while limiting undesired infection of comparator cells.
Normal-cell replication, cytotoxicity, cytokine release, payload-related flags, and study-planning issues that could affect later validation.
Readiness for optimized construction, potency assay development, combination testing, in vivo efficacy, or biodistribution studies.
The workflow can start from a concept, published design, BAC or plasmid system, existing recombinant HSV, or troubleshooting request. The output is a practical candidate recommendation and validation plan.
Define target indication, HSV backbone, attenuation goal, payload concept, entry strategy, available materials, and decision criteria.
Finalize deletion, insertion, promoter, payload, reporter, retargeting, or safety-control architecture with assay endpoints defined.
Generate or receive engineered oHSV candidates, plasmids, BACs, viral stocks, infected cell lysates, or comparator constructs.
Assess genome identity, infectious titer, plaque phenotype, replication kinetics, and selected stability readouts.
Measure tumor infection, cytotoxicity, payload expression, immune activity, receptor dependence, and normal-cell comparator response.
Integrate engineering design, virology, payload, selectivity, and safety evidence into a next-step plan.
Deliverables are organized to connect design choices with rescue feasibility, virus quality, biological activity, selectivity, and next-step development needs.
Backbone review, deletion/insertion strategy, payload cassette notes, retargeting concept, safety-control plan, and proposed validation endpoints.
Confirms that engineering choices match the biological objective and available rescue or validation system.
Rescue observations, plaque purification notes, stock preparation, infectious titer, genome confirmation, and handling notes when included in scope.
Connects recombinant virus generation with identity, titer, and early usability metrics.
Replication kinetics, infection selectivity, receptor dependence, payload expression, tumor killing, immune readouts, or comparator response data.
Interprets potency with viral fitness and selectivity rather than treating each endpoint separately.
Normal-cell comparator results, attenuation-related interpretation, payload risk flags, stability observations, and study-planning considerations.
Supports early exclusion or redesign before larger validation investment.
Ranked candidate recommendation, design risks, follow-up optimization options, and suggested next studies for in vitro, in vivo, or combination programs.
Makes the reasoning behind advancement, redesign, or deprioritization clear to project stakeholders.
This service is most useful when the goal is to refine how an HSV candidate replicates, expresses payloads, enters target cells, or behaves in safety-oriented validation models.
Tune replication control while retaining enough viral fitness for productive tumor infection and lysis.
Insert and compare therapeutic, imaging, reporter, or safety-related transgenes without losing rescue and replication performance.
Evaluate whether glycoprotein engineering improves receptor-dependent tumor entry and lowers unwanted infection.
Build oHSV candidates that express immune-stimulatory payloads or support checkpoint blockade, cell therapy, or vaccine strategies.
Add or evaluate promoter control, miRNA detargeting, reporter-tracer, suicide-gene, or other control elements.
Resolve low rescue efficiency, weak payload expression, unstable insert, poor replication, or unclear tumor selectivity.
oHSV engineering requires attention to HSV genome biology, attenuation logic, entry glycoproteins, payload expression, rescue feasibility, and validation context. Creative Biolabs supports researchers with platform-aware design and decision-oriented evidence generation.
Engineering plans account for HSV genome capacity, neurovirulence-related attenuation, glycoprotein entry biology, insertion locus selection, and rescue workflow.
Projects can begin with design concepts, published architectures, BAC systems, plasmids, viral stocks, prototype candidates, or troubleshooting data.
oHSV engineering can connect to construction, payload screening, promoter control, detargeting, in vitro validation, and in vivo preclinical studies.
Identity, titer, replication, payload, tropism, and stability results are interpreted together to avoid advancing fragile designs.
Reports translate engineering and assay data into candidate recommendations, redesign options, and next-step study requirements.
Questions about construction versus engineering, attenuation, payload insertion, glycoprotein retargeting, safety-oriented testing, starting materials, and validation planning.
oHSV construction focuses on generating a recombinant herpes simplex virus from a defined design. oHSV engineering starts with the design question: which attenuation, replication-control, glycoprotein, promoter, payload, or safety architecture should be used, how it affects viral fitness and tumor selectivity, and what validation evidence is needed before the candidate moves forward.
Creative Biolabs can support backbone review, ICP34.5-, ICP47-, UL39-, TK-, US11-, or related locus design review, tumor-selective promoter or miRNA detargeting-compatible architecture, payload insertion planning, reporter design, glycoprotein retargeting concepts, rescue feasibility, amplification, titer testing, stability checks, and fit-for-purpose validation.
Yes. oHSV offers substantial genetic capacity for cytokines, chemokines, checkpoint modulators, antibodies, bispecific engagers, suicide genes, enzymes, reporter genes, imaging-related genes, and combination-oriented payloads. Payload design should consider insertion locus, promoter strength, expression timing, secretion or membrane anchoring, viral replication burden, and downstream potency readouts.
Retargeting strategies may include gD, gB, gH/gL, or other entry-related glycoprotein design concepts, ligand or antibody-fragment fusion, receptor usage modification, and entry restriction approaches. Each design must be assessed for rescue feasibility, infectivity, receptor-dependent entry, normal-cell reduction, replication behavior, and genetic stability.
Early safety-oriented evaluation may include normal cell comparators, tumor-selective replication assays, neurovirulence-related design review, replication kinetics, cytotoxicity profiling, payload-related risk flags, miRNA detargeting or promoter-control review, stability monitoring, and in vivo study planning when the candidate is ready for animal model work.
Useful materials include the HSV backbone or strain, genome map, plasmid or BAC information, intended deletion or insertion locus, payload sequence, promoter or targeting concept, desired attenuation profile, target tumor type, cell models, normal cell comparators, route of administration, available viral stock or rescue data, and intended next development milestone.
Yes. Engineering can be connected to in vitro infection, replication, payload expression, cytotoxicity, immune activation, normal-cell comparator assays, and in vivo efficacy, biodistribution, safety, viral shedding, or combination therapy studies depending on the program stage and biosafety requirements.
To discuss an oncolytic HSV engineering project, please share your HSV backbone or strain, genome map, BAC or plasmid status, intended deletion or insertion locus, payload sequence, promoter or retargeting concept, desired attenuation profile, target tumor type, cell models, normal-cell comparators, delivery route, existing viral stock or rescue data, biosafety context, and intended next milestone. Creative Biolabs can help design a service plan that connects oHSV engineering, construction, quality control, and validation endpoints.